Study of persimmon leaf flavonoids ameliorates liver steatosis by activating autophagy and antioxidant stress in NAFLD rats

doi:10.11958/20230145

Abstract

Abstract:

Objective To investigate the effect and mechanism of persimmon leaf flavonoids (PLF) on nonalcoholic fatty liver disease (NAFLD) in rats. Methods Male SD rats were fed the high-fat diet for 12 weeks to prepare a NAFLD rat model. The model rats were randomly divided into the model group, the shuilinjia group (28 mg/kg), the PLF group (200 mg/kg) and the PLF+autophagy inhibitor group (PLF+3-MA group, 200 mg/kg PLF+2 mg/kg 3-MA). Another normal SD male rats were selected as the control group, with 6 rats in each group. After treatment for 6 weeks, Hematoxylin-eosin (HE) staining was used to observe changes of liver morphology and pathology. The liver index was calculated. Total cholesterol (TC), triacylglycerol (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum were detected by automatic biochemical analyzer. The contents of superoxide dismutase (SOD) and malondialdehyde (MDA) in liver tissue were determined with microcalorimetric method. Western blot assay was performed to detect expression levels of nuclear factor erythroid 2 related factor 2 (Nrf2), autophagy protein sequencosome-1/protein 62 (SQSTM-1/P62) and microtubule associated protein 1 light chain 3-Ⅱ (LC3-Ⅱ). Results In the control group, there was no significant abnormality in the morphology of hepatocytes, while in the model group, there were fat vacuoles and inflammation in liver cells. Compared with the control group, the liver index, levels of TC, TG, LDL-C, ALT, AST and MDA were increased in the model group, and the expression level of P62 increased, while levels of HDL-C and SOD were decreased, expression levels of Nrf2 and LC3-Ⅱ decreased (P<0.05). Compared with the model group, the fat vacuoles and inflammation were significantly improved in the shuilinjia group and the PLF group. The liver index, levels of TC, TG, LDL-C, ALT, AST and MDA were decreased in the shuilinjia group and the PLF group, and the expression level of P62 decreased, while the level of SOD was increased, expression levels of Nrf2 and LC3-Ⅱ increased (P<0.05). The improvement effect on blood lipid levels, SOD and MDA indicators, as well as marker proteins were lower in the PLF+3-MA group than those of the PLF group. Conclusion PLF has protective effect on liver of NAFLD rats by activating autophagy and antioxidant stress.

Key words: flavones, non-alcoholic fatty liver disease, autophagy, oxidative stress, persimmon leaf flavonoids

CLC Number:

R575.5

Figures/Tables 8

References 20

[1]	段琼, 张紫行, 徐娟, 等. 高尿酸血症与脂肪肝关联的前瞻性队列研究[J]. 中华疾病控制杂志, 2022, 26(12):1420-1425,1432.
	DUAN Q, ZHANG Z X, XU J, et al. A prospective cohort study on the relationship between hyperuricemia and fatty liver[J]. Chin J Dis Control Prev, 2022, 26(12):1420-1425,1432. doi:10.16462/j.cnki.zhjbkz.2022.12.010.
[2]	HUANG T D, BEHARY J, ZEKRY A, et al. Non-alcoholic fatty liver disease:A review of epidemiology,risk factors,diagnosis and management[J]. Intern Med J, 2020, 50(9):1038-1047. doi:10.1111/imj.14709.
[3]	ESLAM M, NEWSOME P N, SARIN S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1):202-209. doi:10.1016/j.jhep.2020.03.039.
[4]	唐东晖, 钟艳花. 藿朴夏苓汤通过AMPK通路干预非酒精性脂肪肝病小鼠的作用机制研究[J]. 中药新药与临床药理, 2020, 31(7):794-801.
	TANG D H, ZHONG Y H. The protective effect of Huo Pu Xia Ling Tang on nonalcoholic fatty liver mice induced by high fat diet by regulating AMPK activity[J]. Traditional Chinese Drug Research & Clinical Pharinacology, 2020, 31(7):794-801. doi:10.19378/j.issn.1003-9783.2020.07.008.
[5]	LINDENMEYER C C, MCCULLOUGH A J. The natural history of nonalcoholic fatty liver disease-an evolving view[J]. Clin Liver Dis, 2018, 22(1):11-21. doi:10.1016/j.cld.2017.08.003.
[6]	蔡江帆, 陈民利. 非酒精性脂肪肝炎动物模型的研究概况[J]. 中国实验动物学报, 2021, 29(1):128-136.
	CAI J F, CHEN M L. Research progress on animal models of nonalcoholic steatohepatitis[J]. Acta Lab Anim Sci Sin, 2021, 29(1):128-136. doi:10.3969/j.issn.1005-4847.2021.01.019.
[7]	王雨露, 许笑阳, 俞晓菡, 等. 氧化应激与自噬在肝细胞癌发生发展中的作用[J]. 临床肝胆病杂志, 2020, 36(2):426-429.
	WANG Y L, XU X Y, YU X H, et al. Role of oxidative stress and autophagy in the development and progression of hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(2):426-429. doi:10.3969/j.issn.1001-5256.2020.02.042.
[8]	李绍波, 刘雪梅, 毕倩宇, 等. 柿叶总黄酮对急性肝损伤小鼠肝组织的保护作用[J]. 西北药学杂志, 2020, 35(1):72-76.
	LI S B, LIU X M, BI Q Y, et al. Protective effect of persimmon leaf total flavonoids on acute liver injury in mice[J]. Northwest Pharmaceutical Journal, 2020, 35(1):72-76. doi:10.3969/j.issn.1004-2407.2020.01.017.
[9]	王翠荣, 成芳梅, 黄斌, 等. 柿叶水提取物对异烟肼和利福平联用所致小鼠肝损伤的保护作用及机制研究[J]. 广西医科大学学报, 2020, 37(1):37-43.
	WANG C R, CHENG F M, HUANG B, et al. Protective effect and mechanism of water extract from persimmon leaves on liver injury induced by isoniazid and rifampicin in mice[J]. Journal of Guangxi Medical University, 2020, 37(1):37-43. doi:10.16190/j.cnki.45-1211/r.2020.01.005.
[10]	魏超, 程文红, 韩春丽. 柿叶提取物对老年原发性高脂血症患者血脂水平影响研究[J]. 数理医药学杂志, 2018, 31(8):1206-1207.
	WEI C, CHENG W H, HAN C L. Effect of persimmon leaf extract on blood lipid level in elderly patients with primary hyperlipidemia[J]. Journal of Mathematical Medicine, 2018, 31(8):1206-1207. doi:10.3969/j.issn.1004-4337.2018.08.046.
[11]	成芳梅, 王翠荣, 黄斌, 等. 柿叶水提取物对对乙酰氨基酚诱导小鼠肝损伤的保护作用及机制[J]. 广西医科大学学报, 2020, 37(2):203-208.
	CHENG F M, WANG C R, HUANG B, et al. Protective effect and mechanism of WEPL on APAP-induced liver injury in mice[J]. Journal of Guangxi Medical University, 2020, 37(2):203-208. doi:10.16190/j.cnki.45-1211/r.2020.02.009.
[12]	岳明强. 加味三才汤对糖尿病SD大鼠肝脏脂肪变性和keap1-Nrf2通路影响的实验研究[D]. 成都: 成都中医药大学, 2015.
	YUE M Q. The experimental research of effects of supplemented San-Cai decotion on liver fatty degeneration and keap1-Nrf2 transduction in diabetic SD rats[D]. Chengdu: Chengdu University of Traditional Chinese Medicine, 2015.
[13]	高永峰, 高允生, 辛晓明. 柿叶总黄酮对糖尿病小鼠降血糖降血脂作用及其机制研究[J]. 泰山医学院学报, 2009, 30(4):245-247.
	GAO Y F, GAO Y S, XIN X M. Hypoglycemic and hypocholesterolaemia effect of Total flavonoids from persimmon leaf in alloxan-induced diabetic mice and its mechanism[J]. Journal of Taishan Medical College, 2009, 30(4):245-247. doi:10.3969/j.issn.1004-7115.2009.04.002.
[14]	吴鹏波, 宋琪, 俞媛洁, 等. 姜黄素激活自噬干预非酒精性脂肪肝病模型大鼠氧化应激及炎症反应[J]. 中国组织工程研究, 2020, 24(11):1720-1725.
	WU P B, SONG Q, YU Y J, et al. Curcumin ameliorates inflammatory reaction and oxidative stress through activation of autophagy in experimental non-alcoholic fatty liver disease rats[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(11):1720-1725. doi:10.3969/j.issn.2095-4344.2505.
[15]	BEN M D, POLIMENI L, BARATTA F, et al. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease[J]. Br J Clin Pharmacol, 2017, 83(1):88-95. doi:10.1111/bcp.12899.
[16]	DONGIOVANNI P, LANTI C, RISO P, et al. Nutritional therapy for nonalcoholic fatty liver disease[J]. J Nutr Biochem, 2016, 29:1-11. doi:10.1016/j.jnutbio.2015.08.024.
[17]	SALOMONE F, GODOS J, ZELBER-SAGI S. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives[J]. Liver Int, 2016, 36(1):5-20. doi:10.1111/liv.12975.
[18]	SUN R B, XU D, WEI Q L, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model[J]. Biomed Pharmacother, 2020, 123:109721. doi:10.1016/j.biopha.2019.109721.
[19]	陆孝良, 蒋元烨, 曹勤. 氧化应激与核因子E2相关因子2在代谢相关脂肪性肝病中的作用[J]. 临床肝胆病杂志, 2020, 36(4):924-927.
	LU X L, JIANG Y Y, CAO Q. The role of oxidative stress and nuclear factor erythroid2-related factor2 in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(4):924-927. doi:10.3969/j.issn.1001-5256.2020.04.048.
[20]	KHAMBU B, YAN S M, HUDA N, et al. Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease[J]. Liver Res, 2018, 2(3):112-119. doi:10.1016/j.livres.2018.09.004.

组别	TC	TG	HDL-C	LDL-C
对照组	1.23±0.09	0.34±0.08	0.54±0.06	0.22±0.06
模型组	2.15±0.41^a	0.52±0.11^a	0.38±0.04^a	0.68±0.09^a
水林佳组	1.34±0.27^b	0.30±0.04^b	0.31±0.02^b	0.26±0.06^b
PLF组	1.04±0.21^b	0.22±0.06^b	0.31±0.03^b	0.19±0.04^bc
PLF+3-MA组	1.71±0.22^d	0.34±0.08^d	0.32±0.03	0.29±0.04^d
F	17.120^＊＊	11.963^＊＊	41.480^＊＊	67.921^＊＊

组别	TC	TG	HDL-C	LDL-C
对照组	1.23±0.09	0.34±0.08	0.54±0.06	0.22±0.06
模型组	2.15±0.41^a	0.52±0.11^a	0.38±0.04^a	0.68±0.09^a
水林佳组	1.34±0.27^b	0.30±0.04^b	0.31±0.02^b	0.26±0.06^b
PLF组	1.04±0.21^b	0.22±0.06^b	0.31±0.03^b	0.19±0.04^bc
PLF+3-MA组	1.71±0.22^d	0.34±0.08^d	0.32±0.03	0.29±0.04^d
F	17.120^＊＊	11.963^＊＊	41.480^＊＊	67.921^＊＊

组别	ALT/（U/L）	AST/（U/L）	肝指数/%
对照组	54.48±3.50	119.78±10.46	2.64±0.31
模型组	74.75±5.09^a	176.87±12.94^a	4.48±0.83^a
水林佳组	54.58±5.00^b	131.42±10.60^b	2.72±0.29^b
PLF组	48.92±3.57^bc	102.17±10.60^bc	2.69±0.36^b
PLF+3-MA组	51.72±3.45	140.45±10.20^d	2.73±0.19
F	35.934^＊＊	38.405^＊＊	18.487^＊＊

组别	ALT/（U/L）	AST/（U/L）	肝指数/%
对照组	54.48±3.50	119.78±10.46	2.64±0.31
模型组	74.75±5.09^a	176.87±12.94^a	4.48±0.83^a
水林佳组	54.58±5.00^b	131.42±10.60^b	2.72±0.29^b
PLF组	48.92±3.57^bc	102.17±10.60^bc	2.69±0.36^b
PLF+3-MA组	51.72±3.45	140.45±10.20^d	2.73±0.19
F	35.934^＊＊	38.405^＊＊	18.487^＊＊

组别	SOD/（U/g）	MDA/（nmol/g）
对照组	106.91±9.50	23.99±2.99
模型组	39.13±7.07^a	98.33±9.76^a
水林佳组	75.85±8.62^b	36.34±5.76^b
PLF组	101.17±10.22^bc	31.68±5.45^b
PLF+3-MA组	53.33±7.81^d	44.10±6.43^d
F	68.246^＊＊	126.744^＊＊